PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
No Data
No Data available this quarter, please select a different quarter.
-0.01
Net cash position versus Biotechnology median net debt of 0.41. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
-5.62
Negative coverage while Biotechnology median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
0.00
Current ratio below 50% of Biotechnology median of 2.89. Michael Burry would check for immediate refinancing needs.
No Data
No Data available this quarter, please select a different quarter.